GLSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Greenwich Lifesciences Inc (GLSI) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are neutral, there are no recent positive trading signals, and the financial performance remains weak despite some improvement in losses. While the analyst rating and price target increase are encouraging, the lack of significant catalysts and weak trading trends suggest holding off for now.
The MACD histogram is negative (-0.896) and contracting, indicating a lack of bullish momentum. The RSI is neutral at 38.852, and moving averages are converging, suggesting no clear trend. The stock is trading below the pivot point (26.624), with support at 23.926 and resistance at 29.323. Overall, the technical indicators do not signal a strong buying opportunity.
H.C. Wainwright raised the price target to $50 from $39, citing positive efficacy in the Phase 3 FLAMINGO-01 trial of GLSI-100, which reduced breast cancer recurrence by 80% in the non-HLA-A*02 arm. This could potentially double the market for GLSI-100.
Additionally, the stock has an 80% chance of declining in the short term (-2.57% in the next day, -4.86% in the next week).
In Q3 2025, the company reported no revenue growth (0% YoY) and a net loss of -$4.15M, though this was an improvement of 55.57% YoY. EPS improved to -0.3, up 50% YoY. Despite these improvements, the company remains unprofitable.
H.C. Wainwright maintains a Buy rating and increased the price target to $50, citing positive trial data for GLSI-100. This reflects optimism about the company's future prospects in the breast cancer treatment market.
